Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Gene therapies are physically out of reach for many patients, on top of their cost, according to a new PwC Health Research Institute report.
Why it matters: This further exacerbates the rural-urban divide in access to care.
By the numbers: The report looks at 4 treatments approved in the U.S. In 13 states, none of the 4 treatments were available, as of July. And there are only 5 zip codes nationwide in which all 4 are available.
Between the lines: These treatments can be prohibitively expensive even for patients with access to them.
- The gene therapy Zolgensma is the most expensive drug in the world, with a list price of $2.1 million.
- There are also affordability questions surrounding CAR-T, as hospitals often aren't fully compensated for the cost of administering it.
What we're watching: There are 30 gene therapies in late-stage testing, per PwC, and the number of clinical trials has grown rapidly over the last decade.
Go deeper: The real drug pricing debate is upon us